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A B S T R A C T
Catheter ablation of atrial fibrillation (AF) has been increasingly employed as a thera-
peutic modality to maintain sinus rhythm. However, the procedure is potentially as-
sociated with major complications and its long-term efficacy is relatively poor. Thus, 
the quest for additional non-pharmacological, non-ablative therapies for the manage-
ment of patients with AF continues. Present methodology for catheter ablation of AF 
includes pulmonary vein isolation by applying radiofrequency current around the pul-
monary vein ostia, in order to prevent the ectopic activity arising from the pulmonary 
veins from reaching the atria and thereby inducing AF. However, this approach failed 
to answer the fundamental question of how the generally short episodes of focal firing 
in the pulmonary veins are converted into AF. Experimental work has provided many 
lines of evidence linking the intrinsic cardiac autonomic nervous system with focal 
firing from the pulmonary veins via activation of the ganglionated plexi (GP) adjacent 
to these veins. Autonomic denervation is common following pulmonary vein isolation 
and has been associated with decreased risk of AF recurrence. Recent clinical stu dies 
where GP ablation was performed either in addition to the standard procedure of 
pulmonary vein isolation, or as a stand-alone procedure support these experimental 
data. These intriguing new concepts and data linking the autonomic nervous system 
to AF will herein be briefly reviewed.
A T R i A l  F i B R i l l A T i o n :  E p i d E m i o l o g y  
A n d  C u R R E n T  T R E A T m E n T  o p T i o n S
Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia 
and is associated with increased cardiovascular morbidity and mortality.1,2 Although 
a rhythm control strategy may offer no survival benefit over a rate control strategy 
for older individuals,3,4 current guidelines acknowledge that for younger individuals, 
especially those with paroxysmal AF, rhythm control may be a better initial approach.5 
The currently available treatment options for maintenance of sinus rhythm in patients 
with AF include anti-arrhythmic drugs and surgical or catheter ablation.5 Anti-ar-
rhythmic drug therapy is recommended as first line for maintenance of sinus rhythm, 
whereas catheter ablation, previously recommended as second line therapy, after 
anti-arrhythmic drugs have failed,5 may be appropriate as first line therapy for some 
patients.6 However, anti-arrhythmic drug therapy is associated with inconsistent efficacy 
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and potential toxicity, including proarrhythmia.5 On the other 
hand, catheter ablation, despite being more efficacious than 
anti-arrhythmic drugs, is still suboptimal in maintaining sinus 
rhythm in the long term. Specifically, the long-term efficacy 
of catheter ablation for AF, as reported recently by 2 very 
experienced centers, is relatively poor, ranging from 29% to 
46% at 5 years after a single procedure.7,8 Moreover, catheter 
ablation is associated with a major complication rate of about 
5-6%, including cardiac tamponade, pulmonary vein stenosis, 
phrenic nerve injury, esophageal injury/ left atrial fistula and 
thromboembolism.5,9 The number of patients with AF in the 
US is expected to increase to more than 5.6 million by the 
year 2050 as the population ages.2 Considering the current 
long-term success rate of catheter ablation, the development of 
additional non-pharmacological, non-ablative therapies could 
play a significant role in the management of patients with AF.
A T R i A l  F i B R i l l A T i o n :  T h E  R o l E  o F 
T h E  i n T R i n S i C  C A R d i A C  A u T o n o m i C 
n E R v o u S  S y S T E m
The intrinsic cardiac autonomic nervous system consists 
of an extensive epicardial neural network forming numerous 
ganglionated plexi (GP) not only on the atria, but also on both 
ventricles. These GP, most of which are embedded within 
epicardial fat pads, vary in size, from those that contain just a 
few neurons, to those that contain over 200 neurons.10,11 Several 
studies have demonstrated that the GP are composed of effer-
ent, afferent and interconnecting neurons, which contain both 
sympathetic and parasympathetic elements, in addition to a 
variety of neuropeptides and neuromodulators.12,13 Of interest, 
the four largest GP lie adjacent to the four pulmonary veins.10,11 
A seminal observation by Haissaguerre and co-workers es-
tablished the role of the pulmonary veins in the pathogenesis 
of AF. These investigators found that the majority of their 
patients with drug-resistant paroxysmal AF manifested rapid 
focal firing arising from the myocardial sleeves of the pulmo-
nary veins.14,15 This focal firing was responsible for initiating 
and often maintaining episodes of AF. This breakthrough 
observation laid the foundation for the present methodol-
ogy for catheter ablation of AF, which includes pulmonary 
vein isolation by applying radiofrequency current around the 
pulmonary vein ostia, in order to prevent the ectopic activity 
arising from the pulmonary veins from reaching the atria and 
thereby inducing AF.16,17 However, this approach failed to 
answer the fundamental question of how the generally short 
episodes of focal firing in the pulmonary veins are converted 
into AF, nor did it answer why pulmonary veins rather than 
other atrial regions become the sites of focal firing in those 
patients with drug-resistant AF. Recently, a series of basic ex-
periments provided many lines of evidence linking the intrinsic 
cardiac autonomic nervous system with focal firing from the 
pulmonary veins. Scherlag et al18 demonstrated that stimuli ap-
plied to pulmonary veins would not induce AF unless there was 
simultaneous activation of the GP adjacent to that pulmonary 
vein. Importantly, the GP stimulation was achieved with high 
frequency (20 Hz) and very short duration (0.1 ms) pulses at a 
voltage which did not excite the atrial muscle but did activate 
the neurons found in the GP. In another series of experiments, 
Po et al19 showed that injection of the neurotransmitter ace-
tylcholine into the GP induced, within minutes, premature 
beats and sustained AF arising from adjacent pulmonary veins. 
Additional in vitro studies by Patterson et al20,21 demonstrated 
that pulmonary vein myocytes have cellular electrophysiologi-
cal properties distinctive from adjacent atrium, particularly, 
a shorter action potential duration and greater sensitivity to 
autonomic stimulation, which facilitates the initiation of AF. 
Under conditions of local stimulation of both parasympathetic 
and sympathetic nerve endings,21 or simultaneous administra-
tion of acetylcholine plus norepinephrine (or isoproterenol),20 
early afterdepolarizations were induced, giving rise to rapid, 
non-sustained triggered firing from canine pulmonary veins, 
similar to the focal firing observed in patients with paroxysmal 
AF. In pulmonary vein myocytes, early afterdepolarizations are 
facilitated because of the temporal discrepancy between the 
abbreviated action potential duration and the longer calcium 
transient. Under autonomic stimulation (parasympathetic 
and sympathetic) these differences are further exacerbated 
so the sodium-calcium exchanger extrudes Ca++, bringing 
in 3 Na+ and a net positive charge into the pulmonary vein 
myocytes, thereby leading to early afterdepolarizations and 
triggered firing.20 Triggered firing from the pulmonary veins 
is suppressed by muscarinic cholinergic receptor blockade, 
beta-adrenoceptor antagonism, inhibition of calcium tran-
sients, or sodium-calcium exchange blockade.21 Therefore, 
parasympathetic activation which causes action potential 
shortening, and sympathetic activation which enhances the 
calcium transient are important and necessary components 
for such triggered firing.
Autonomic denervation is common following pulmonary 
vein isolation22-24 and has been associated with decreased risk 
of AF recurrence.22,25,26 In a recent elegant study, Lemola et 
al27 investigated the role of pulmonary veins versus the GP in 
maintenance of experimental vagal AF. These investigators 
performed pulmonary vein isolation in dogs while preserving 
the GP and in others ablated the GP while leaving the pulmo-
nary veins intact. They demonstrated that intact pulmonary 
veins are not needed to maintain experimental vagal AF, 
whereas ablation of GP prevented AF. The same group of 
investigators expanded these results in a different experimental 
model of AF showing that pulmonary veins play a minor role 
in AF induced by chronic rapid atrial pacing, whereas intact 
GP play an important role in AF maintenance in the pres-
ence of rapid atrial pacing-induced remodeling.28 It should be 
noted, however, that the specific neural elements within the 
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GP (efferent, afferent or interconnecting neurons) which are 
responsible for the beneficial results of GP ablation remain 
unclear. Clinical studies showing that complete electrical isola-
tion of the pulmonary veins is not necessary for maintenance 
of sinus rhythm support these experimental data.29,30 These 
investigations suggest that it is the GP associated with the 
pulmonary veins and not the pulmonary veins themselves that 
are important in the pathogenesis of AF and that the interrup-
tion of axons from these hyperactive GP to pulmonary veins 
may have also contributed to procedural success. Interruption 
of the axons may explain the usual elimination of pulmonary 
vein firing by pulmonary vein isolation. Recent animal data 
have provided evidence that GP hyperactivity manifests clini-
cally as complex fractionated atrial electrograms (CFAE).31 
In this canine model, the distribution of the CFAE correlated 
well with the locations of the GP, consistent with the original 
clinical report by Nademanee et al,32 and the CFAE were 
eliminated by ablating the GP at a distance.31 In the clinical 
electrophysiological laboratory, we have shown that the de-
gree of fractionation was markedly reduced by GP ablation.33 
Although the response of CFAE to atropine administered 
intravenously in patients with AF has not been consistent 
among different studies,34,35 the overall evidence suggests that 
the autonomic nervous system plays an important role in the 
formation of CFAE.36
Recent clinical studies where GP ablation was performed, 
either in addition to the standard procedure of pulmonary vein 
isolation,37,38 or as a stand-alone procedure,39-41 support these 
experimental data. In these studies, the overall success rate of 
the procedure in eliminating AF was significantly increased 
with the addition of GP ablation by approximately 25%,37,38 
whereas GP ablation alone was successful in 71% to 86% 
of the patients.39-41 However, these additional lesions create 
large areas of scarring in the left atrium that might promote 
iatrogenic arrhythmia formation, i.e. macro-reentrant atrial 
tachycardia (left atrial flutter).42 In these cases, second and 
third ablation procedures may be required to close gaps which 
allow reentry. In addition, GP ablation alone is not sufficient 
to treat longstanding persistent AF, as indicated by the poor 
success rate of the procedure in this group of patients.43 There-
fore, although GP ablation is a promising modality for the 
treatment of paroxysmal AF, it is limited by certain caveats, as 
described above, which make it a less than an ideal treatment 
option. Surgical techniques have also used the combination 
of pulmonary vein isolation with GP ablation.44 Minimally 
invasive, thoracoscopic surgical ablation procedures, combin-
ing epicardial pulmonary vein isolation with GP ablation, have 
been shown to achieve freedom from atrial tachyarrhythmias 
of approximately 80%, without major adverse cardiac events 
at 1 year of follow-up.45-47 However, despite the promising 
results of surgical pulmonary vein isolation and GP ablation, 
data from randomized clinical trials are scarce. 
l o W  l E v E l  v A g u S  n E R v E 
S T i m u l A T i o n :  A  n o n - A B l A T i v E  n o n -
p h A R m A C o l o g i C  T R E A T m E n T  F o R  A F
Autonomic neuromodulation is a novel therapeutic ap-
proach that takes advantage of the plasticity of the neural tissue 
to shape it to our advantage without injuring it and has been 
successfully used in some diseases. Vagus nerve stimulation de-
livered through an implantable device is being frequently used 
for the treatment of drug-refractory epilepsy.49,50 Preliminary 
studies of the use of vagus nerve stimulation in patients with 
heart failure showed promising results, including improvement 
in heart failure functional class, quality of life, left ventricular 
ejection fraction and left ventricular end-systolic volume.51,52 
In experimental models, vagal activation protects the heart 
from ventricular arrhythmia during myocardial infarction53 and 
limits infarct size.54 Importantly, recent evidence supports the 
emergence of low level vagal nerve stimulation (LLVNS) as 
a novel non-pharmacological, non-ablative treatment modal-
ity for AF. We have recently shown that LLVNS, at voltages 
substantially below that which slows the sinus rate or atrio-
ventricular conduction, significantly increases the effective 
refractory period (ERP) in the atria as well as the pulmonary 
vein myocardium, suppresses AF inducibility and decreases 
AF duration, induced by strong cholinergic stimulation.55-59 
In those experiments, LLVNS was applied to both vagal 
trunks dissected in the neck or to the vagal pre-ganglionics at 
the posterior wall of the superior vena cava.58 We have also 
provided evidence that the effects of LLVNS were mediated 
by inhibition of GP activity.56-58 Ganglionated plexi inhibition 
was indicated by LLVNS-mediated suppression of the ability 
of the anterior right GP stimulation to slow the heart rate. In 
addition, there was marked suppression of the frequency and 
amplitude of the neural activity recorded from the anterior 
right GP or superior left GP.56-58 Furthermore, LLVNS of the 
right vagus nerve alone was sufficient to exert a strong anti-
arrhythmic action by suppressing the neural activity of both 
the adrenergic and the cholinergic component of the intrinsic 
cardiac autonomic nervous system.59 The anti-arrhythmic ef-
fects of LLVNS were also observed in ambulatory dogs. In 
this experimental model, left-sided LLVNS suppressed left 
stellate ganglion neural activity, especially in the morning and 
decreased tyrosine-hydroxylase positive cells in the left stellate 
ganglion 1 week after cessation of LLVNS.60 Moreover, in the 
same study, LLVNS prevented paroxysmal atrial tachycardia 
and paroxysmal AF induced by rapid atrial pacing.60 Based on 
the observation that transcutaneous electrical stimulation of 
the tragus, the anterior protuberance of the outer ear, where 
the auricular branch of the vagus nerve is located, elicits evoked 
potentials in the brainstem in humans,61 we recently demon-
strated that AF inducibility can be suppressed by stimulation 
of the tragus in dogs.62 A promising clinical implication of 
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these results is that intermittent transcutaneous LLVNS can 
be used as a non-invasive approach to terminate or prevent 
paroxysmal AF. Further studies are required to test the utility 
of this treatment modality in humans.
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